Loading…
← CockpitCompetitor Analysis › 086450.KS DongKook Pharmaceutical Co., Ltd.Open in the cockpit ↗

DongKook Pharmaceutical Co., Ltd.086450.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major
Momentum leader 93
Mkt cap
$855M
US dollars, full cap
Free float
55%
of shares outstanding
$/day
$8.59M
20-day average traded
Fwd P/E
14.0×
forward earnings
ROIC−WACC
+3.0 pp
WACC 5.5%
Hurdle
-15 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · KRW₩24,400
1D-1.6%
1W-5.2%
1M-2.6%
3M+23.7%
6M+8.9%
YTD+42.3%
1Y+38.6%
ATR %7.3%
52w lowhigh21.9% off high

What DongKook Pharmaceutical does

Employees: 1,306

DongKook Pharmaceutical at a glance

Size DongKook Pharmaceutical (086450.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $855M, the 264th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩24,400 on 18 Nov 2026.

Performance Over six months the shares gained 8.9%, against -22.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue grew 13.0% over the last twelve months (peer median +3.6%); the operating margin is 10.0% (peer median 2.7%).

Valuation It trades at 14.0× forward earnings against a peer median of 24.7× (4th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.0 points above its cost of capital (5.5% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026086450.KS 108Peer median 77
Six months, rebased to 100: DongKook Pharmaceutical against the median of its 20 peers (local-currency closes).

DongKook Pharmaceutical financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.01T₩927B₩812B₩731B₩662B
Revenue growth—+14%+11%+10%—
Gross profit₩549B₩492B₩440B₩405B₩375B
EBITDA₩136B₩128B₩108B₩88.0B₩91.4B
Net income₩69.7B₩66.0B₩61.2B₩47.2B₩52.9B
Free cash flow₩27.7B₩29.5B₩50.9B₩9.64B₩1.99B
Capital expenditure₩69.1B₩46.0B₩30.8B₩39.4B₩51.2B
Total debt₩71.1B₩76.2B₩80.7B₩105B₩91.4B

Quarterly statements and history in the cockpit →

DongKook Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%069620688176CRVS4521688621600771006120PHARMSANOFICONR300267000813603229002082000597AKTS6078688553COLL086450.KS6-month return →1-month return →
Up and to the right = strong over both horizons. DongKook Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×0696204521688621600771PHARMSANOFICONR6078COLL086450.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. DongKook Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-40%-20%0%20%600771PHARMSANOFICONR0020820005976078688553COLL086450.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. DongKook Pharmaceutical is the large dot.

DongKook Pharmaceutical competitors and peer comparison

How DongKook Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

DongKook Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure086450.KSPeer medianRank in peer set
1-month return-2.6%-10.3%9th highest of 21
6-month return+8.9%-22.0%2nd highest of 19
Distance from 52-week high-21.9%-42.6%3rd highest of 21
Revenue growth (TTM)+13.0%+3.6%7th highest of 19
Operating margin10.0%2.7%6th highest of 19
Forward P/E14.0×24.7×4th cheapest of 9
Growth the price implies (Req g, 7 yrs)-4.2%11.2%2nd least demanding of 9
Growth delivered (Del g)+10.6%+8.3%5th highest of 9
Hurdle (Req g minus delivered)-14.8 pp-5.9 pp3rd least demanding of 9
ROIC minus cost of capital+3.0 pp-2.9 pp3rd highest of 17
EV / EBITDA8.8×8.4×4th most expensive of 8
Net debt / EBITDA-0.3×1.8×4th least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%10.4×4.6%+22.5%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%3.7×-2.6%+20.3%

Questions

Which companies are DongKook Pharmaceutical's closest peers?
The cockpit's peer set: Daewoong Pharm (069620.KS), Jiangsu Yahong Meditech (688176.SS), Corvus Pharmaceuticals (CRVS), Kaken Pharmaceutical (4521.T), City Therapeutics (CTY), Beijing Sun-Novo Pharmaceutical Research (688621.SS), GuangYuYuan Chinese Herbal Medicine (600771.SS), SK Discovery (006120.KS).
Is DongKook Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 14.0× against a peer median of 24.7×, 4th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.
How has DongKook Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned +8.9% against -22.0% for the median peer; over one year +38.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.